GO:0008209 androgen metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008209 androgen metabolic process describes the chemical reactions and pathways involving androgens, C19 steroid hormones that stimulate male sexual characteristics.
• Androgen excess is a hallmark of polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age.
• Idiopathic hirsutism is defined by androgen excess without ovulatory dysfunction or hyperandrogenemia, highlighting the need for precise androgen profiling.
• Key genes in androgen metabolism include SRD5A1, SRD5A2, AKR1C3, CYP17A1, HSD17B3, and AR, which are targets for functional studies.
• CRISPR knockout, point mutation, and knock-in models enable causal interrogation of androgen-metabolic genes in vitro and in vivo.
• Understanding androgen metabolic process is critical for developing therapies for PCOS, hirsutism, and androgen-secreting tumors.
Description
Androgen metabolic process (GO:0008209) encompasses the chemical reactions and pathways involving androgens, which are C19 steroid hormones that can stimulate the development of male sexual characteristics. This biological process is fundamental to reproductive endocrinology, influencing sexual differentiation, pubertal development, and metabolic homeostasis. Dysregulation of androgen metabolism underlies a spectrum of disorders, from polycystic ovary syndrome (PCOS) to androgen-secreting adrenal tumors. Researchers study this process to identify therapeutic targets and biomarkers for androgen excess conditions. The QuickGO definition provides a framework for understanding the enzymatic steps and regulatory mechanisms that convert precursor steroids into active androgens such as testosterone and dihydrotestosterone. This article synthesizes authoritative data and real PubMed literature to provide a research-grade overview of GO:0008209, covering its definition, mechanisms, key genes, disease associations, and experimental models.
androgen metabolic process At A Glance
| GO ID | GO:0008209 |
|---|---|
| GO term | androgen metabolic process |
| Ontology | biological_process |
| Synonym | androgen metabolism |
| Major function | Chemical reactions and pathways involving androgens, C19 steroid hormones that stimulate male sexual characteristics |
| Parent term | steroid metabolic process |
| Related diseases | Polycystic ovary syndrome, idiopathic hirsutism, androgen-secreting adrenal tumors |
| Key enzymes | SRD5A1, SRD5A2, AKR1C3, CYP17A1, HSD17B3 |
What Is GO:0008209?
GO:0008209 androgen metabolic process is defined as the chemical reactions and pathways involving androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics. This process includes the biosynthesis, conversion, and degradation of androgens such as testosterone, dihydrotestosterone (DHT), and androstenedione. It is a biological process that occurs in steroidogenic tissues including the gonads, adrenal cortex, and peripheral tissues. The term is synonymous with androgen metabolism and is a child of steroid metabolic process. In the context of QuickGO, this term captures the enzymatic and regulatory steps that maintain androgen homeostasis, which is critical for normal physiology and is disrupted in various endocrine disorders.
Why Is androgen metabolic process Important in Cell Biology?
Androgen metabolic process is critically important because androgens are central to reproductive health, and their dysregulation leads to prevalent disorders such as PCOS, which affects up to 15% of women of reproductive age. Understanding the enzymatic pathways and regulatory networks of androgen metabolism provides insights into disease mechanisms and identifies potential therapeutic targets. Moreover, androgen metabolism intersects with metabolic syndrome, cardiovascular risk, and cancer biology, making it a high-priority area for biomedical research.
• PCOS is the most common cause of androgen excess and a leading cause of infertility.
• Idiopathic hirsutism affects a significant proportion of women and requires exclusion of other hyperandrogenic disorders.
• Androgen-secreting adrenal tumors are rare but can cause severe virilization and require surgical intervention.
• Androgen metabolism influences bone density, muscle mass, and libido in both sexes.
• Enzymes like SRD5A2 are targets for 5-alpha reductase inhibitors used in benign prostatic hyperplasia and androgenetic alopecia.
• Androgen receptor signaling is a key driver in prostate cancer, linking androgen metabolism to oncology.
• Genetic variants in HSD17B3 and AKR1C3 are associated with disorders of sex development and androgen excess.
• CRISPR-based models allow precise dissection of androgen metabolic pathways for drug discovery.
• Biomarkers of androgen metabolism, such as testosterone and DHEAS, are used in clinical diagnostics.
• Understanding androgen metabolism is essential for developing personalized therapies for hyperandrogenic conditions.
What Happens During androgen metabolic process?
Biosynthesis of Androgen Precursors
In simple terms: The body starts making androgens from cholesterol through a series of enzymatic steps.
Androgen biosynthesis begins with cholesterol, which is converted to pregnenolone and then to dehydroepiandrosterone (DHEA) via CYP17A1. DHEA is subsequently converted to androstenedione, a key precursor for active androgens. This process occurs primarily in the adrenal cortex and gonads and is regulated by ACTH and LH.
Conversion to Active Androgens
In simple terms: Enzymes modify androstenedione to produce testosterone and DHT, the most potent androgens.
Androstenedione is converted to testosterone by 17beta-hydroxysteroid dehydrogenase type 3 (HSD17B3) in the testes, while in peripheral tissues, AKR1C3 can catalyze similar reactions. Testosterone is further reduced to dihydrotestosterone (DHT) by 5-alpha reductase enzymes SRD5A1 and SRD5A2. DHT binds the androgen receptor with higher affinity than testosterone, amplifying androgenic effects.
Peripheral Androgen Metabolism
In simple terms: Androgens are further processed in tissues like skin and fat to be activated or inactivated.
In peripheral tissues, androgens undergo interconversion and conjugation. For example, SRD5A1 in the skin converts testosterone to DHT, contributing to hirsutism. Conversely, glucuronidation and sulfation in the liver facilitate androgen excretion. These pathways are critical for maintaining androgen homeostasis and are often dysregulated in hyperandrogenic states.
Regulation of Androgen Levels
In simple terms: The body controls androgen levels through feedback loops involving the brain and gonads.
The hypothalamic-pituitary-gonadal (HPG) axis regulates androgen production via gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Insulin and insulin-like growth factor 1 (IGF-1) also modulate androgen synthesis, particularly in PCOS. Dysregulation of these feedback mechanisms leads to androgen excess.
Androgen Action and Clearance
In simple terms: Androgens bind to receptors in cells to exert effects and are eventually broken down.
Androgens exert their effects by binding to the androgen receptor (AR), a nuclear receptor that regulates gene expression. After action, androgens are metabolized in the liver and excreted. Impaired clearance can contribute to androgen accumulation and associated pathologies.
Key Genes Involved in GO:0008209 androgen metabolic process
The following genes encode enzymes, receptors, and regulatory proteins that are central to androgen metabolic process and are frequently studied in endocrine research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRD5A1 | Converts testosterone to DHT in peripheral tissues | Target for 5-alpha reductase inhibitors; studied in hirsutism and PCOS |
| SRD5A2 | Converts testosterone to DHT in prostate and genital skin | Mutations cause 5-alpha reductase deficiency; target for BPH drugs |
| AKR1C3 | Catalyzes conversion of androstenedione to testosterone | Overexpressed in PCOS and prostate cancer; potential therapeutic target |
| CYP17A1 | Catalyzes 17-alpha-hydroxylase and 17,20-lyase activities | Key enzyme in androgen biosynthesis; mutations cause 17-alpha-hydroxylase deficiency |
| HSD17B3 | Converts androstenedione to testosterone | Mutations cause 46,XY DSD; studied in androgen production |
| AR | Mediates androgen signaling | Mutations cause androgen insensitivity syndrome; target in prostate cancer |
| CYP11A1 | Catalyzes cholesterol side-chain cleavage | Rate-limiting step in steroidogenesis; studied in adrenal tumors |
| CYP21A2 | 21-hydroxylase involved in cortisol and aldosterone synthesis | Deficiency causes congenital adrenal hyperplasia with androgen excess |
| HSD3B2 | Converts DHEA to androstenedione | Mutations cause 3-beta-HSD deficiency; relevant to androgen synthesis |
| STAR | Transports cholesterol into mitochondria | Essential for steroidogenesis; mutations cause lipoid CAH |
| INSR | Insulin receptor signaling | Insulin resistance contributes to androgen excess in PCOS |
| IGF1 | Growth factor that amplifies androgen synthesis | Elevated in PCOS; studied as therapeutic target |
| SHBG | Binds androgens, regulating free hormone levels | Low SHBG increases free testosterone; biomarker in PCOS |
| CYP19A1 | Aromatase converts androgens to estrogens | Inhibitors used in PCOS; studied for androgen balance |
| DHEAS | Major circulating androgen precursor | Biomarker for adrenal androgen excess |
| FKBP5 | Co-chaperone regulating AR sensitivity | Modulates androgen response; studied in PCOS |
| SRD5A3 | Involved in N-linked glycosylation and steroid metabolism | Emerging role in androgen metabolism; under investigation |
| AKR1C2 | Reduces DHT to less active metabolites | Contributes to androgen inactivation; studied in prostate cancer |
How Is androgen metabolic process Regulated?
Androgen metabolic process is regulated at multiple levels. The hypothalamic-pituitary-gonadal axis controls gonadal androgen production through LH and FSH. Insulin and IGF-1 enhance ovarian and adrenal androgen synthesis, particularly in PCOS. Enzymatic activity of SRD5A1, SRD5A2, and AKR1C3 is modulated by genetic polymorphisms and hormonal signals. Additionally, the androgen receptor feedback loop and co-regulators such as FKBP5 influence androgen sensitivity. Dysregulation of these pathways leads to hyperandrogenic states.
androgen metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP17A1 | PCOS, androgen-secreting tumors | Knockout in H295R adrenal cells; point mutation in ovarian theca cells |
| SRD5A2 | Idiopathic hirsutism, 5-alpha reductase deficiency | Knock-in of polymorphic variants in keratinocytes; knockout in prostate cancer cells |
| AR | Androgen insensitivity syndrome, prostate cancer | Point mutation knock-in in LNCaP cells; knockout in PCOS models |
| AKR1C3 | PCOS, prostate cancer | Overexpression in HEK293 cells; knockout in prostate cancer organoids |
| HSD17B3 | 46,XY DSD | Knockout in Leydig cells; knock-in of patient mutations |
Polycystic Ovary Syndrome (PCOS)
PCOS is the most common endocrine disorder in women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Androgen excess in PCOS arises from increased ovarian and adrenal androgen production, driven by insulin resistance and elevated LH. Key genes such as CYP17A1, AKR1C3, and SRD5A1 are implicated in PCOS pathogenesis. Research models using CRISPR knockout of these genes in ovarian theca cells can elucidate their causal roles.
Idiopathic Hirsutism
Idiopathic hirsutism is defined as excessive hair growth in women with normal ovulatory function and normal circulating androgen levels. It is thought to result from increased peripheral sensitivity to androgens, often due to elevated 5-alpha reductase activity in hair follicles. Studies have shown that SRD5A1 and SRD5A2 polymorphisms may contribute to this condition. CRISPR point mutation models can help dissect the contribution of these variants to enzyme activity.
Androgen-Secreting Adrenal Tumors
Androgen-secreting adrenal tumors are rare but can cause severe virilization and are often malignant. These tumors overexpress steroidogenic enzymes such as CYP11A1 and CYP17A1, leading to excessive androgen production. Surgical resection is the primary treatment, but molecular understanding is limited. CRISPR knockout of CYP17A1 in adrenal tumor cell lines can reveal dependencies and potential therapeutic targets.
Androgen Insensitivity Syndrome and Prostate Cancer
Mutations in the androgen receptor (AR) cause androgen insensitivity syndrome, a disorder of sex development. Conversely, AR signaling is a driver in prostate cancer, where androgen metabolic enzymes like SRD5A2 and AKR1C3 are therapeutic targets. CRISPR knock-in of AR mutations can model resistance to anti-androgen therapies.
From androgen metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SRD5A2 variant increase DHT production? | Point mutation knock-in in HEK293 or keratinocytes |
| Is CYP17A1 essential for ovarian androgen synthesis? | CRISPR knockout in human theca cells |
| Can AKR1C3 overexpression drive androgen excess? | Overexpression in adrenal or ovarian cell lines |
| What is the role of AR mutations in androgen insensitivity? | Knock-in of AR mutations in patient-derived fibroblasts |
| Does HSD17B3 knockout affect testosterone production? | Knockout in mouse Leydig cell line or in vivo model |
| Can CRISPR library screening identify new androgen regulators? | Genome-wide knockout library in steroidogenic cells |
How to Study the androgen metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Concentrations of androgens | Quantifying testosterone and DHT in cell media |
| Enzyme activity assay | Catalytic activity of SRD5A or AKR1C3 | Assessing impact of point mutations |
| RNA-seq | Gene expression changes | Identifying compensatory pathways after knockout |
| Proteomics | Protein abundance and modifications | Validating enzyme expression in CRISPR models |
| Luciferase reporter assay | Androgen receptor transcriptional activity | Evaluating AR mutations or androgen sensitivity |
| Immunofluorescence | Localization of steroidogenic enzymes | Studying subcellular distribution in tissues |
| CRISPR library screening | Genome-wide fitness and androgen production | Discovering novel regulators of androgen metabolism |
Steroid Hormone Profiling
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying androgens such as testosterone, DHT, and androstenedione in cell culture media and serum. This method enables precise measurement of androgen metabolic flux and is essential for validating CRISPR models.
Enzyme Activity Assays
Enzymatic activities of SRD5A1, SRD5A2, and AKR1C3 can be measured using radiolabeled substrates or fluorogenic probes. These assays are used to assess the impact of point mutations or knockouts on catalytic efficiency.
Transcriptomic and Proteomic Analysis
RNA-seq and quantitative proteomics can reveal changes in expression of androgen-metabolic genes following CRISPR editing. These approaches identify compensatory pathways and regulatory networks.
Reporter Assays for Androgen Receptor Activity
Androgen receptor transcriptional activity is measured using luciferase reporter constructs containing androgen response elements. This method is used to evaluate the functional impact of AR mutations or altered androgen levels.
How CRISPR Can Be Used to Study GO:0008209 androgen metabolic process
Knockout
CRISPR knockout of androgen-metabolic genes such as CYP17A1, SRD5A2, or AKR1C3 in steroidogenic cell lines (e.g., H295R, KGN) ablates enzyme function, allowing researchers to measure the resulting changes in androgen production and identify essential genes. Knockout models are also used to validate drug targets.
Point Mutation
Point mutations identified in patients with disorders of androgen metabolism (e.g., SRD5A2, HSD17B3) can be introduced via CRISPR base editing or homology-directed repair to study their functional consequences on enzyme activity and androgen levels. This approach provides insights into genotype-phenotype correlations.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags into endogenous androgen-metabolic loci enables real-time tracking of enzyme expression and localization. Knock-in of disease-associated variants (e.g., AR mutations) creates isogenic models for drug testing.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like AKR1C3 or SRD5A1 can model androgen excess states. Overexpression in cell lines or organoids allows researchers to study the effects of increased enzyme dosage on androgen production and downstream signaling.
How EDITGENE Supports androgen metabolic process Research
Researchers studying androgen metabolic process-related genes often need to determine whether a candidate gene is causally involved in androgen production or action. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery, from knockout to precise point mutation and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for androgen metabolic process research.
Frequently Asked Questions About androgen metabolic process
What is androgen metabolic process?
Androgen metabolic process (GO:0008209) is the set of chemical reactions and pathways involving androgens, C19 steroid hormones that stimulate male sexual characteristics.
What genes are involved in androgen metabolic process?
Key genes include SRD5A1, SRD5A2, AKR1C3, CYP17A1, HSD17B3, and AR, which encode enzymes and receptors critical for androgen synthesis and action.
How is androgen metabolic process related to PCOS?
PCOS is characterized by androgen excess, often due to increased ovarian and adrenal androgen production driven by insulin resistance and elevated LH.
What is idiopathic hirsutism?
Idiopathic hirsutism is excessive hair growth in women with normal ovulatory function and normal androgen levels, thought to result from increased peripheral androgen sensitivity.
Which enzymes convert testosterone to DHT?
5-alpha reductase enzymes SRD5A1 and SRD5A2 convert testosterone to dihydrotestosterone (DHT), the most potent androgen.
How can CRISPR be used to study androgen metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the causal roles of specific genes in androgen production and action.
What are the symptoms of androgen excess?
Symptoms include hirsutism, acne, alopecia, and ovulatory dysfunction, commonly seen in PCOS and other hyperandrogenic disorders.
What is the role of the androgen receptor?
The androgen receptor (AR) mediates the effects of androgens by regulating gene expression; mutations cause androgen insensitivity syndrome and drive prostate cancer.
How are androgen levels measured?
Androgen levels are typically measured using LC-MS/MS, which quantifies testosterone, DHT, and other steroids with high sensitivity.
What are androgen-secreting adrenal tumors?
These are rare tumors that overproduce androgens, leading to virilization; they often involve overexpression of steroidogenic enzymes like CYP17A1.
Conclusion
Androgen metabolic process (GO:0008209) is a fundamental biological pathway with broad implications for reproductive health and disease. Dysregulation of androgen synthesis and action underlies prevalent conditions such as PCOS, idiopathic hirsutism, and adrenal tumors. Advances in CRISPR gene editing have provided powerful tools to study these pathways with unprecedented precision. By leveraging knockout, point mutation, knock-in, and overexpression models, researchers can uncover causal mechanisms and identify new therapeutic targets. EDITGENE is committed to supporting this research with comprehensive CRISPR services and bioinformatics expertise.
References
- 1. Azziz R et al.. 2016. Polycystic ovary syndrome.. Nat Rev Dis Primers 2:16057 PMID: 27510637
- 2. Cussen L et al.. 2022. Approach to androgen excess in women: Clinical and biochemical insights.. Clin Endocrinol (Oxf) 97(2):174-186 PMID: 35349173
- 3. Azziz R et al.. 2000. Idiopathic hirsutism.. Endocr Rev 21(4):347-62 PMID: 10950156
- 4. Rittmaster RS. 1997. Hirsutism.. Lancet 349(9046):191-5 PMID: 9111556
- 5. de Kroon RWPM et al.. 2022. Is idiopathic hirsutism idiopathic?. Clin Chim Acta 531:17-24 PMID: 35292252
- 6. Yildiz BO et al.. 2010. Visually scoring hirsutism.. Hum Reprod Update 16(1):51-64 PMID: 19567450
- 7. Esquivel-Zuniga MR et al.. 2022. Non-PCOS Hyperandrogenic Disorders in Adolescents.. Semin Reprod Med 40(1-02):42-52 PMID: 35052005
- 8. Sciarra F et al.. 1995. Androgen-secreting adrenal tumors.. Minerva Endocrinol 20(1):63-8 PMID: 7651284
